Generic drug company Synthon Pharmaceuticals has received tentative U.S. Food and Drug Administration approval on its application to make a version of UCB‘s (EBR:UCB) allergy medicine Xyzal.
Netherlands-based Synthon, which has its U.S. headquarters and laboratories in Research Triangle Park, North Carolina, said it is seeking to bring a generic version of Xyzal oral solution to the U.S. market with partner Perrigo (NASDAQ:PRGO). Michigan-based Perrigo is a maker of over-the-counter and generic pharmaceuticals.
The New Blueprint: How Clever Care Health Plan is Scaling Its Member Experience [Video]
MedCity News was at the Vive conference and spoke with executives who shared their insights for the healthcare industry.
Synthon said it believes it is the first to file an application with the FDA for a Xyzal generic. Being first to file gives Synthon the advantage of 180 days of marketing exclusivity over other Xyzal generics.
The FDA approved Belgium-based UCB’s antihistamine Xyzal in 2007. The drug has been marketed in the United States by partner Sanofi-Aventis (NYSE:SNY). It has been available in Europe since 2001.
Zyrtec, another UCB allergy drug, and Xyzal combined to generate $755.2 million in global sales in 2006. But Zyrtec’s sales suffered upon entry of generics into the market. Now Xyzal appears to be facing the same fate. Xyzal generates about $15 million in annual sales, according to information and publishing firm Wolters Kluwer.